Skip to main content

Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes

A CME-certified, ABO MOC-eligible Activity

Click here to complete your registration.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.


Thursday, December 1, 2022

7:30 - 8:30 PM ET (6:30 - 7:30 PM CT / 4:30 - 5:30 PM PT


  • Welcome and Introduction
  • Current State of Retinal Disease Management
  • Clinical Updates for New and Emerging Retinal Disease Therapies 
  • Q&A Session and Activity Roundup


The prevalence of retinal diseases such as age-related macular degeneration and diabetic macular edema is projected to rise dramatically in the coming decades with an aging population and the increasing prevalence of diabetes.

The availability of anti-vascular endothelial growth factor (VEGF) therapies has significantly improved outcomes for patients with retinal disease for over a decade. However, the need for frequent intravitreal injections required to obtain the best possible patient outcomes with anti-VEGF therapies has added to the patient burden associated with retinal disease management. This also led many clinicians and patients to opt for as-needed dosing intervals guided by optical coherence tomography results, which may be more expedient for patients but has also been associated with worsening of retinal disease and vision loss. Thus, an unmet need persists for more efficacious therapies with increased duration of response to minimize the number of injections required for the many patients with retinal disease. There are newly available therapeutic options, such as the port delivery system with ranibizumab and the dual anti-VEGF, anti-Ang-2 binding faricimab; along with several emerging, novel therapies including sustained-release anti-VEGF formulations, combination anti-VEGFs, and gene therapy.

The program, “Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies and the Potential for Improved Patient Outcomes” will deliver much-needed, up-to-date information on evidence-based strategies for dosing available anti-VEGF therapies and for integrating newly approved therapies into practice; with reviews of current clinical data from emerging retinal disease therapies.


Nancy Holekamp, MD
Professor of Clinical Ophthalmology and Visual Sciences
Washington University School of Medicine
St Louis, MO
Director of Retina Services
Pepose Vision Institute
Chesterfield, MO

Carl Regillo, MD
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA

This intended audience for this educational initiative is ophthalmologists and clinicians who manage patients with retinal disease.

At the conclusion of this activity, participants should be able to:

  • Assess risk/benefits of fixed, frequent dosing intervals versus individualized dosing intervals for anti-VEGF therapies
  • Select anti-VEGF dosing intervals that provide the best potential outcomes for patients with retinal disease
  • Assess the safety and efficacy of recently approved and emerging retinal disease therapies

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email

ABO MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement for the American Board of Opthalmology's Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. 

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABO MOC points, your information will be shared with the ABO through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABO records.

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of the activity is vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships will be mitigated by PCME.

Disclosure and mitigation information will be made known to the participants prior to the start of the activity.

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.


  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)


  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)


  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

DSL/cable (wired connection recommended)

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by

Supported by an educational grant from Genentech, a member of the Roche Group.

PCME Privacy Policy